View Post

Breast Cancer Becomes Vulnerable to Immune Cells Through DDR1 Deactivation

In In The News by Barbara Jacoby

From: genengnews.com Immune exclusion, or the lack of immune cells in the vicinity of cancer cells, predicts poor patient outcomes in multiple cancers, including triple-negative breast cancer (TNBC). Now, researchers have identified a key molecule, discoidin domain receptor 1 (DDR1), that prevents immune cells from entering tumors and killing the cancer cells inside through the formation of the extracellular matrix (ECM). …

View Post

Gilead, Merck to study combination therapy for breast cancer

In In The News by Barbara Jacoby

By: PBR Staff Writer From: pharmaceutical-business-review.com Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC). Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients …

View Post

Cleveland Clinic launching breast cancer vaccine trial

In In The News by Barbara Jacoby

By: Justin Boggs From: spectrumnews1.com What You Need To Know Cleveland Clinic’s vaccine trial will target triple-negative breast cancer, which is considered the most aggressive form of the cance The Cleveland Clinic will enroll 18-24 women who previously had cancer and are at a high risk of recurrence A study in mice showed that a single vaccine could prevent tumors …

View Post

Trodelvy Improves QOL in Triple-Negative Breast Cancer

In In The News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com At the European Society for Medical Oncology (ESMO) virtual meeting, new data from the phase III ASCENT study was presented showing that patients with treatment-resistant metastatic triple-negative breast cancer (TNBC) who received sacituzumab govitecan (Trodelvy) had significant and clinically meaningful improvements in health-related quality of life (QOL). In this exclusive MedPage Today video, co-investigator Kevin …

View Post

Team discovers novel strategy to tame aggressive breast cancer and starts clinical trial

In Clinical Studies News by Barbara Jacoby

By: National Cancer Centre Singapore From: medicalxpress.com A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less …

View Post

Study finds increased risk of triple negative breast cancers among Black women

In In The News by Barbara Jacoby

Source: University of Pennsylvania From: news-medical.net An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S. health systems underscores the importance of understanding the heterogeneity of breast cancer risk factors for women of differing races, ages, and disease subtypes. The study, led by researchers in the Perelman School of Medicine at the University of …

View Post

HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer

In Clinical Studies News by Barbara Jacoby

Source: HUTCHMED (China) Limited From: globenewswire.com HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021. This trial is to explore the potential for …

View Post

Leronlimab Provides a Significant Survival Benefit in Metastatic Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Ariana Pelosci From: cancernetwork.com Leronlimab yielded a notable increase in overall survival and progression-free survival in patients with metastatic triple-negative breast cancer. The use of leronlimab (PRO 140) in patients with metastatic triple-negative breast cancer (mTNBC) resulted in a notable increase in both overall survival (OS) and progression-free survival (PFS), according to a press release on a phase 1b/2 …

View Post

SITC Releases Immunotherapy Clinical Practice Guideline for Breast Cancer

In In The News by Barbara Jacoby

By: Dylann Cohn-Emery From: targetedonc.com In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer (TNBC), the Society for Immunotherapy of Cancer (SITC) has published clinical practice guidelines for physicians treating in this setting.1 “Immunotherapy is now offering some patients with breast cancer clinically meaningful benefit in early stage and advanced disease,” Jennifer Litton, MD, …

View Post

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Breast Cancer Now From: news-medical.net An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer. Used in combination, aspirin and avelumab could potentially stop people dying from this disease. The clinical trial is being funded by the Breast Cancer Now Catalyst …